Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

R. Seban,John S. Nemer,Aurélien Marabelle,Randy Yeh,Eric Deutsch,Samy Ammari,A. Moya-Plana,Fatima-Zohra Mokrane,Robyn D. Gartrell,Grace G. Finkel,Luke W. Barker,Amélie Bigorgne,Lawrence H. Schwartz,Yvonne M. Saenger,Caroline Robert,Laurent Dercle

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics

2019

R. Seban
John S. Nemer
Aurélien Marabelle
Randy Yeh
Eric Deutsch
Samy Ammari
A. Moya-Plana
Fatima-Zohra Mokrane
Robyn D. Gartrell
Grace G. Finkel
Luke W. Barker
Amélie Bigorgne
Lawrence H. Schwartz
Yvonne M. Saenger
Caroline Robert
Laurent Dercle

Purpose An imaging-based stratification tool is needed to identify melanoma patients who will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying biomarkers for survival and response evaluated in lymphoid tissue metabolism in spleen and bone marrow before initiation of therapy.

Keywords:

Antibody
Medicine
Lymphatic system
Pathology
Biomarker (medicine)
Bone marrow
Immunotherapy
Spleen
Cancer research
Transcriptome
Melanoma
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations